Close Menu

NEW YORK – Twist Bioscience said Wednesday after the close of the market that it has priced an underwritten public offering of approximately 4.6 million shares of common stock at $28 per share.

The San Francisco-based synthetic DNA producer expects gross proceeds of about $130 million from the offering, above its previous expectation of $100 million. It will use the funds invest in R&D, scale commercial operations, and expand production capacity.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.